NEW YORK (GenomeWeb News) – The US Food and Drug Administration has named Janet Woodcock director of the agency’s Center for Drug Evaluation and Research.
Woodcock was previously director of CDER between 1994 and 2005. She has also served as deputy director of the FDA’s Center for Biologics, Evaluation and Research, director of the Office of Therapeutics, Research and Review, and she has held other positions at the FDA, including deputy commissioner for operations. She has been interim director of CDER since October.
"Dr. Woodcock's exemplary service since October was confirmation of her being ideally suited to lead the Center during this crucial period following the passage of the Food and Drug Administration Amendments Act of 2007," FDA Commissioner Andrew von Eschenbach said in a statement.
Febit has appointed Michelle Lyles to be VP of marketing and sales. Lyles formerly was vice president of sales and marketing with Genospectra, technology manager for high-throughput screening systems at PerkinElmer, and a product manager at Packard Biosciences.
Helicos BioSciences said this week that senior VP and CFO Louise Mawhinney has resigned and will leave the company on March 19. Helicos President and COO Steve Lombardi will serve as interim CFO and company controller Kevin Lafond will perform principal accounting duties while the company searches for a replacement CFO.
High Throughput Genomics has made several management additions, hiring John Luecke to be senior product manager and Julie Capadona to be marketing communications manager, as well as tapping Shervin Kamkar as North West senior account executive and Gordon Hunter as Mid West senior account executive.
Thermo Fisher Scientific has given CEO Marijn Dekkers a 2007 cash bonus of $1.9 million and plans to pay him an annual salary after March 2008 of $1.17 million with a target bonus for 2008 of 125 percent of that salary.
The company has given Executive VP Marc Casper $825,000 for the 2007 bonus and a 2008 salary of $700,000; Senior VP and CFO Peter Wilver received $513,000 for a 2007 bonus and will receive $565,000 in salary in 2008; the company gave Senior VP Guy Broadbent $315,000 in 2007 bonus, and he will receive $515,000 in 2008 salary; and the company has given Senior VP, General Counsel, and Secretary Seth Hoogasian $357,000 for a 2007 bonus and $450,000 in 2008 salary.
Coprorate finance lawyer Charles Morton has been appointed to the board of directors of the Maryland Technology Development Corporation.
Peter Byers has been awarded the March of Dimes/Colonel Harland Sanders Award for lifetime achievement in the field of genetic sciences. Byers, who helped to establish guidelines for molecular genetic pathology, is on the faculty of the Department of Pathology and Medicine at the University of Washington.
AlphaSniffer has appointed William Freytag chairman of its board of directors. Freytag has served as chairman and CEO of Aspreva Pharmaceuticals, president and CEO of Myogen, senior VP of technology and business development at Somatogen, as well as other biotechnology positions.
Caliper Life Sciences’ Chairman of the Board of Directors Daniel Kisner will not seek re-election for his position when it expires at the next stockholder meeting. Instead of appointing a replacement, Caliper plans to allow its board to shrink from eight to seven members. Kisner has agreed to serve the company as a consultant.
Donald Hawker has been named director of business development for Monarch LifeSciences’ western region. Hawker has been director of marketing and sales at Aspectrics, and he has been involved in marketing and development at Proteomatch and at Coalesce Corporation.
Caprotec Bioanalytics has appointed Mathias Grote to be chief scientific officer and chief financial officer. Grote formerly was CEO of Pelias, senior VP of commercial operations at Intercell, and chief business officer at Noxxon.
ThermoGenesis has named Mahendra Rao, who is VP of Stem Cells and Regenerative Medicine at Invitrogen, to its board of directors. Rao has been chairman of the FDA’s Cell and Gene Therapy Advisory Committee, and he is the founder of Q Therapeutics.
PerkinElmer revealed in a filing with the US Securities and Exchange Commission today that Executive Chairman Greg Summe, who served as CEO during 2007, received total compensation of $10.95 million in 2007. The compensation includes salary, bonuses, and other stock and option awards. Current CEO and President Robert Friel received total compensation of $5.1 million, while CFO Jeffrey Capello received $2.27 million, Chief Administrative Officer Richard Walsh received $2.37 million, and President of Optoelectronics John Roush received $1.98 million.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.